SCHEMBL314433

SCHEMBL314433

C[C@H]1CNc2cc(Cl)ccc2-n2c(-c3cc(Cl)ccc3F)nnc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.37
OPRK1 P41145 3/20 0.35
PDE4D Q08499 2/20 0.35
SLC22A1 O15245 1/20 0.35
ABCB11 O95342 1/20 0.35
CYP3A4 P08684 1/20 0.35
DRD3 P35462 1/20 0.35
GABRA1 P14867 2/20 0.34
GABRA5 P31644 2/20 0.34
GABRA3 P34903 2/20 0.34
GABRA2 P47869 2/20 0.34
GABRG2 P18507 1/20 0.34
HTR2A P28223 1/20 0.34
GABRB3 P28472 1/20 0.34
ADRA1A P35348 1/20 0.34
AVPR1A P37288 2/20 0.34
BRD4 O60885 10/20 0.34
P2RX7 Q99572 1/20 0.33
HPGD P15428 2/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314431 1.00 HSD11B1 (0.37) HSD11B1OPRK1PDE4DSLC22A1ABCB11
SCHEMBL314432 1.00 HSD11B1 (0.37) HSD11B1OPRK1PDE4DSLC22A1ABCB11
SCHEMBL314165 0.93 HSD11B1 (0.34) HSD11B1OPRK1PDE4DSLC22A1ABCB11
SCHEMBL314164 0.93 HSD11B1 (0.34) HSD11B1OPRK1PDE4DSLC22A1ABCB11
SCHEMBL314166 0.93 HSD11B1 (0.34) HSD11B1OPRK1PDE4DSLC22A1ABCB11
SCHEMBL314816 0.91 HSD11B1 (0.37) HSD11B1OPRK1PDE4DSLC22A1ABCB11
SCHEMBL315207 0.91 HSD11B1 (0.37) HSD11B1OPRK1PDE4DSLC22A1ABCB11
SCHEMBL315208 0.91 HSD11B1 (0.37) HSD11B1OPRK1PDE4DSLC22A1ABCB11
SCHEMBL314594 0.91 BRD4 (0.38) BRD4P2RX7LMNABRD2
SCHEMBL314596 0.91 BRD4 (0.38) BRD4P2RX7LMNABRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US claimed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 HSD11B1 1123/4885OPRK1 3019/4885PDE4D 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.